Financials in USD. Standardized financial statements.
A compact view of how Cellyan Biotechnology Co., Ltd turns revenue into operating income and net income.
| Metric | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|
| Revenue? | $20.31M | $16.69M | $12.56M |
| Revenue Growth? | +21.7% | +32.9% | 0.0% |
| Cost of Revenue? | $17.90M | $13.13M | $9.82M |
| Gross Profit? | $2.42M | $3.56M | $2.74M |
| Gross Margin? | +11.9% | +21.3% | +21.8% |
| Operating Expenses? | $2.28M | $1.95M | $1.70M |
| Operating Income? | $132,038 | $1.61M | $1.04M |
| EBITDA? | $1.21M | $2.53M | $1.76M |
| Income Before Tax | $36,112 | $1.53M | $1.02M |
| Income Tax Expense | $63,168 | $196,252 | $22,574 |
| Net Income? | -$27,056 | $1.33M | $998,196 |
| EPS? | $-0.00 | $0.18 | $0.09 |
| Diluted EPS? | $-0.00 | $0.18 | $0.09 |
Revenue, profitability, margins, EPS, and share-count trends over time.
Top-line demand and scale over time
Profit left after direct production costs
Core business profitability before financing and tax
Bottom-line profit after all expenses
Profit allocated to each diluted share
Share count trend that affects EPS quality
Gross, operating, and net margin quality